BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17389624)

  • 21. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin.
    Borawski J; Naumnik B; Myśliwiec M
    Kidney Int; 2003 Dec; 64(6):2229-37. PubMed ID: 14633147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
    Ivanović V; Demajo M; Krtolica K; Krajnović M; Konstantinović M; Baltić V; Prtenjak G; Stojiljković B; Breberina M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Dimitrijević B
    Clin Chim Acta; 2006 Sep; 371(1-2):191-3. PubMed ID: 16650397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: which dose regimen should be preferred?
    Weiss A; Brose S; Ploetze K; Matschke K
    Clin Hemorheol Microcirc; 2013 Jan; 54(3):249-58. PubMed ID: 23648452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
    Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing.
    Näsström B; Stegmayr B; Gupta J; Olivecrona G; Olivecrona T
    Nephrol Dial Transplant; 2005 Jun; 20(6):1172-9. PubMed ID: 15797889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins.
    Rydzewska-Rosołowska A; Borawski J; Myśliwiec M
    Ren Fail; 2009; 31(9):791-7. PubMed ID: 19925286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transforming growth factor beta at clinical onset of Type 1 diabetes mellitus. A pilot study.
    Flores L; Näf S; Hernáez R; Conget I; Gomis R; Esmatjes E
    Diabet Med; 2004 Aug; 21(8):818-22. PubMed ID: 15270783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The contribution of platelet-derived growth factor, transforming growth factor-beta1, and insulin-like growth factor-I in platelet-rich plasma to the proliferation of osteoblast-like cells.
    Ogino Y; Ayukawa Y; Kukita T; Koyano K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jun; 101(6):724-9. PubMed ID: 16731390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?
    Gritters M; Borgdorff P; Grooteman MP; Schoorl M; Schoorl M; Bartels PC; Tangelder GJ; Nubé MJ
    Nephrol Dial Transplant; 2008 Sep; 23(9):2911-7. PubMed ID: 18364368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enoxaparin does not ameliorate limb ischemia-reperfusion injury.
    Abbruzzese TA; Albadawi H; Kang J; Patel VI; Yoo JH; Lamuraglia GM; Watkins MT
    J Surg Res; 2008 Jun; 147(2):260-6. PubMed ID: 18498878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum transforming growth factor-beta1 and epidermal growth factor in biliary atresia.
    Vejchapipat P; Theamboonlers A; Poomsawat S; Chittmittrapap S; Poovorawan Y
    Eur J Pediatr Surg; 2008 Dec; 18(6):415-8. PubMed ID: 19012231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases.
    Rissmann A; Pieper S; Adams I; Brune T; Wiemann D; Reinhold D
    Pediatr Allergy Immunol; 2009 May; 20(3):261-5. PubMed ID: 18761651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of enoxaparin on myeloperoxidase release during hemodialysis.
    Gozdzikiewicz J; Borawski J; Koc-Zorawska E; Mysliwiec M
    Hemodial Int; 2014 Oct; 18(4):819-24. PubMed ID: 24837008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enoxaparin attenuates endothelial damage with less bleeding compared with unfractionated heparin in endotoxemic rats.
    Iba T; Takayama T
    Shock; 2009 Nov; 32(5):530-4. PubMed ID: 19295478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephromegaly relates to hepatocyte growth factor dysregulation in biliary atresia.
    Tsau YK; Jou ST; Ni YH
    Pediatr Nephrol; 2002 Jul; 17(7):554-9. PubMed ID: 12172775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.
    Zhao L; Sheldon K; Chen M; Yin MS; Hayman JA; Kalemkerian GP; Arenberg D; Lyons SE; Curtis JL; Davis M; Cease KB; Brenner D; Anscher MS; Lawrence TS; Kong FM
    Lung Cancer; 2008 Feb; 59(2):232-9. PubMed ID: 17905467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.